Kazakhstan's central bank announced it will reduce its gold reserves, which currently make up about 78% of total reserves, by around 3% by the end of 2026. The move is driven by attractive US Treasury yields, making dollar assets more appealing than gold. The bank plans to sell physical gold and options to achieve this rebalancing, aiming to maintain liquidity and avoid an overly concentrated portfolio. Despite expecting gold prices to rise slightly, the bank prefers a cautious approach and will monitor market conditions closely.
Kazakhstan's gold reserve plans provide context for Pluang's market snapshot as of Oct 13, 2026 22:41 WIB: Among 150 US stocks, 59 rose and 90 fell. Pinterest Inc (PINS) gained 3.27% to USD 22.12 with 100% sell order activity, contrasting with Grab Holdings Ltd. (GRAB), which dropped 3.02% to USD 3.06 and saw 75% sell orders. Li Auto Inc (LI) rose 3.07% to USD 11.75, with a nearly balanced buy-sell split.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
